Skip to content

Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)

Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00316576
Enrollment
160
Registered
2006-04-21
Start date
2006-05-31
Completion date
2006-11-30
Last updated
2008-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Kidney Failure, Acute

Keywords

Kidney failure, Acute, Genetic Polymorphism, Angiotensin-converting enzyme

Brief summary

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Detailed description

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Interventions

PROCEDUREBlood sampling for PCR

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 yrs * ICU stay \> 48 hours

Exclusion criteria

* Age \< 18 yrs * Creatinine \> 180 µmol/L * Absence of consent

Design outcomes

Primary

MeasureTime frame
Incidence of ARFDuring ICU stay

Secondary

MeasureTime frame
MortalityICU and Hospital mortality

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026